Protagonist Therapeutics
PTGX
PTGX
239 hedge funds and large institutions have $2.78B invested in Protagonist Therapeutics in 2024 Q3 according to their latest regulatory filings, with 77 funds opening new positions, 78 increasing their positions, 64 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
4.13% more ownership
Funds ownership: 100.71% → 104.84% (+4.1%)
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
53% less call options, than puts
Call options by funds: $2.44M | Put options by funds: $5.15M
Holders
239
Holding in Top 10
4
Calls
$2.44M
Puts
$5.15M
Top Buyers
| 1 | +$201M | |
| 2 | +$78M | |
| 3 | +$49.6M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43.8M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$25.4M |
Top Sellers
| 1 | -$66.1M | |
| 2 | -$37.9M | |
| 3 | -$36M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$35.5M |
| 5 |
Millennium Management
New York
|
-$33.2M |